PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 39/09, 39/39, 39/385, A61P 31/04 — A2

(11) International Publication Number: **WO 00/56358**

(43) International Publication Date: 28 September 2000 (28.09.00)

(21) International Application Number: PCT/EP00/02465

(22) International Filing Date: 17 March 2000 (17.03.00)

(30) Priority Data:

9906437.0	19 March 1999 (19.03.99)	GB
9909077.1	20 April 1999 (20.04.99)	GB
9909466.6	23 April 1999 (23.04.99)	GB
9916677.9	15 July 1999 (15.07.99)	GB

(71) Applicant *(for all designated States except US)*: SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B–1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: CAPIAU, Carine [BE/BE]; (BE). DESCHAMPS, Marguerite [BE/BE]; (BE). DESMONS, Pierre, Michel [BE/BE]; (BE). LAFERRIERE, Craig, Antony, Joseph [CA/BE]; (BE). POOLMAN, Jan [NL/BE]; (BE). PRIEELS, Jean–Paul [BE/BE]; SmithKline Beecham Biologicals s.a, Rue de l'Institut 89, B–1330 Rixensart (BE).

(74) Agent: GIDDINGS, Peter, John; SmithKline Beecham Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: VACCINE

(57) Abstract

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular the present invention relates to specific advantageous pneumococcal polysaccharide conjugates adjuvanted with 3D–MPL and substantially devoid of aluminium–based adjuvant.